Contributions
Abstract: P1256
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: CD62L, a molecule also referred as L-selectin, expressed on CD4+ peripheral blood lymphocytes, has recently drawn attention due to its possible relevance as a biomarker predictive of progressive multifocal leukoencephalitis (PML) in patients with multiple sclerosis (MS) under natalizumab, especially when combined with anti-JC virus (JCV) antibody index.
Aim: The present study addresses possible correlation between CD62L expression and anti-JCV antibody index in multiple sclerosis patients under first- and second line disease modifying treatments.
Methods: Forty-four patients under first- (interferon-β, glatiramer acetate) (m:f 13:31, age 41.54 ± 10.19) and 41 patients under second-line (natalizumab, fingolimod) treatment (m:f 13:28, age 40.04±9.95) were included. Frequency of peripheral blood CD62L+ cells (% of CD4+ T-cells), as well as CD62L mean fluorescence intensity (MFI) on CD4+ T-cells were analysed by flow cytometry. Anti-JCV antibody serology was conducted by standard ELISA techniques.
Results: Groups were gender (p=0.83) and age (p=0.5) matched. Patients under second-line treatment exhibited lower mean anti-JCV antibody index compared to first-line treatment group (1.04±1.11 versus 1.93±1.37, p=0.001). Frequency of CD4+CD62L+ T-cells was significantly lower in patients under second- compared to first-line treatment (67.17±18.18 versus 79.79±8.45, respectively, p< 0.001). Also CD62L MFI on CD4+ T-cells was significantly lower in patients under second- compared to first-line treatment (54.96±21.9 versus 72.31±37.33, respectively, p=0.01). In patients under first - line treatment, frequency of CD4+CD62L+ T-cells, as well as CD62L MFI on CD4+ T-cells, did not correlate with anti-JCV antibody index (Pearson"s r=0,14, p=0.35 and Pearson"s r=0.008, p=0.958, respectively). In patients under second-line treatment frequency of CD4+CD62L+ T-cells exhibited a significant negative correlation with anti-JCV antibody index, whereas CD62L MFI on CD4+ T-cells did not show significant correlation (Pearson"s r=-0.571, p< 0.001 and Pearson"s r=0,046, p=0,779, respectively).
Conclusion: These data provide evidence of an inverse association between CD62L expression on T-cells and anti-JCV antibody index in patients under second-line disease modifying treatment. Further prospective studies are needed in order to elucidate potential clinical application of CD62L expression analysis on PML risk prediction, in addition to anti-JCV antibody index.
Disclosure: Boziki MK., nothing to disclose
Papadopoulos G., nothing to disclose
Lagoudaki R., nothing to disclose
Polychroniadou E., nothing to disclose
Bakirtzis Ch., nothing to disclose
Grigoriadis N., nothing to disclose
Karacostas D., nothing to disclose
Abstract: P1256
Type: Poster
Abstract Category: Therapy - disease modifying - Risk management for disease modifying treatments
Background: CD62L, a molecule also referred as L-selectin, expressed on CD4+ peripheral blood lymphocytes, has recently drawn attention due to its possible relevance as a biomarker predictive of progressive multifocal leukoencephalitis (PML) in patients with multiple sclerosis (MS) under natalizumab, especially when combined with anti-JC virus (JCV) antibody index.
Aim: The present study addresses possible correlation between CD62L expression and anti-JCV antibody index in multiple sclerosis patients under first- and second line disease modifying treatments.
Methods: Forty-four patients under first- (interferon-β, glatiramer acetate) (m:f 13:31, age 41.54 ± 10.19) and 41 patients under second-line (natalizumab, fingolimod) treatment (m:f 13:28, age 40.04±9.95) were included. Frequency of peripheral blood CD62L+ cells (% of CD4+ T-cells), as well as CD62L mean fluorescence intensity (MFI) on CD4+ T-cells were analysed by flow cytometry. Anti-JCV antibody serology was conducted by standard ELISA techniques.
Results: Groups were gender (p=0.83) and age (p=0.5) matched. Patients under second-line treatment exhibited lower mean anti-JCV antibody index compared to first-line treatment group (1.04±1.11 versus 1.93±1.37, p=0.001). Frequency of CD4+CD62L+ T-cells was significantly lower in patients under second- compared to first-line treatment (67.17±18.18 versus 79.79±8.45, respectively, p< 0.001). Also CD62L MFI on CD4+ T-cells was significantly lower in patients under second- compared to first-line treatment (54.96±21.9 versus 72.31±37.33, respectively, p=0.01). In patients under first - line treatment, frequency of CD4+CD62L+ T-cells, as well as CD62L MFI on CD4+ T-cells, did not correlate with anti-JCV antibody index (Pearson"s r=0,14, p=0.35 and Pearson"s r=0.008, p=0.958, respectively). In patients under second-line treatment frequency of CD4+CD62L+ T-cells exhibited a significant negative correlation with anti-JCV antibody index, whereas CD62L MFI on CD4+ T-cells did not show significant correlation (Pearson"s r=-0.571, p< 0.001 and Pearson"s r=0,046, p=0,779, respectively).
Conclusion: These data provide evidence of an inverse association between CD62L expression on T-cells and anti-JCV antibody index in patients under second-line disease modifying treatment. Further prospective studies are needed in order to elucidate potential clinical application of CD62L expression analysis on PML risk prediction, in addition to anti-JCV antibody index.
Disclosure: Boziki MK., nothing to disclose
Papadopoulos G., nothing to disclose
Lagoudaki R., nothing to disclose
Polychroniadou E., nothing to disclose
Bakirtzis Ch., nothing to disclose
Grigoriadis N., nothing to disclose
Karacostas D., nothing to disclose